Table 2.
Baseline characteristics of the study population according to the with and without diabetes.
| Variables |
All patients
(n = 276) |
Without diabetes
(n = 200) |
With diabetes
(n = 76) |
P-value |
|---|---|---|---|---|
| Age (years) | 65 ± 11 | 64 ± 11 | 66 ± 9 | 0.156 |
| Female, n (%) | 131 (47.5) | 99 (49.5) | 32 (42.1) | 0.272 |
| Smoking, n (%) | 68 (24.6) | 48 (24.0) | 20 (26.3) | 0.690 |
| Hypertension, n (%) | 198 (71.7) | 134 (67.0) | 64 (84.2) | 0.005 |
| Dyslipidemia, n (%) | 163 (59.1) | 105 (52.5) | 58 (76.3) | <0.001 |
| TG (mmol/L) | 1.43 ± 0.99 | 1.37 ± 0.88 | 1.58 ± 1.22 | 0.125 |
| TC (mmol/L) | 4.42 ± 1.31 | 4.48 ± 1.38 | 4.29 ± 1.14 | 0.282 |
| LDL-C (mmol/L) | 2.63 ± 1.12 | 2.69 ± 1.18 | 2.47 ± 0.95 | 0.167 |
| HDL-C (mmol/L) | 1.25 ± 0.36 | 1.26 ± 0.35 | 1.23 ± 0.38 | 0.401 |
| CAD, n (%) | 123 (44.6) | 78 (39.0) | 45 (59.2) | 0.003 |
| CKD, n (%) | 27 (9.8) | 21 (10.5) | 6 (7.9) | 0.515 |
| Heart failure, n (%) | 20 (7.2) | 12 (6.0) | 8 (10.5) | 0.195 |
| Statins, n (%) | 140 (50.7) | 88 (44.0) | 52 (68.4) | <0.001 |
| ACEI/ARBs, n (%) | 91 (33.0) | 54 (27.0) | 37 (48.7) | 0.001 |
| β-blockers, n (%) | 122 (44.2) | 78 (39.0) | 44 (57.9) | 0.005 |
| Baseline LVEF (%) | 65 (60–68) | 65 (59–68) | 65 (60–68) | 0.471 |
| Baseline Vmax (m/s) | 3.52 ± 0.78 | 3.58 ± 0.80 | 3.34 ± 0.72 | 0.023 |
| Baseline MPG (mmHg) | 29.82 ± 15.40 | 31.10 ± 15.73 | 26.71 ± 13.05 | 0.033 |
| BAV, n (%) | 82 (29.7) | 64 (32.0) | 18 (23.7) | 0.177 |
| Rapid progression, n (%) | 136 (49.3) | 89 (44.5) | 47 (61.8) | 0.010 |
Abbreviations as in Table 1.